期刊文献+

利福布汀治疗幽门螺杆菌感染患者效果初探 被引量:2

下载PDF
导出
摘要 目的浅谈利福布汀治疗幽门螺杆菌感染的临床效果。方法选取2009年2月-2011年4月就诊于我院的幽门螺杆菌感染患者96例,随机平均分为两组,实验组和对照组,每组48例。实验组采用含利福布汀的三联疗法,对照组采用常规的二线四联疗法。对比HP根治率和不良反应情况。结果实验组HP根治率为89.6%;对照组HP根治率为91.7%。对比差异无统计学意义,P>0.05。实验组出现1例白细胞减少症,经治疗好转,对照组未出现白细胞减少症。实验组出现15例不良反应,对照组出现26例不良反应,对比差异有统计学意义,P<0.05。结论利福布汀三联药物治疗幽门螺杆菌感染效果显著,安全,值得推广。
出处 《中外医疗》 2012年第20期105-105,共1页 China & Foreign Medical Treatment
  • 相关文献

参考文献1

二级参考文献86

  • 1Havlir DV,Duble MP,Satter FR.Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin,daily rifabutin,or both N Engi[J].J Med,1996;335:392-8
  • 2Benson CA,Cohn DL,Williams P.For the ACTG 196/CPCRA 009 Study efficacy of clarithromycin(CLA) vs.rifabutin(RBT)vsCLA+RBT for prevention of Mycobacterim avium complex(MAC) disease inHIV+ patients with CD4 counts≤100 cells·μl-1[R].(Abstr.205) 3rd Conference on Retroviruses and Opportunistic Infections.Washington,DC,1996
  • 3Scampini G,Nava A,Newsman AJ,Della-Torre P,Mazue G.Multinucleated hepatocytes induced by rifabutin in rats[J].Toxicol Pathol,1993;21:369-76
  • 4Hellinger FJ.The lifetime cost of treating a person with HIV[J].JAMA,1993;270:474-8
  • 5Moore RD,Keruly JC,Chaisson RE.Costs of treating HIV disease under medicaid in maryland[J].J Acquir immune Defic Syndr Hum Retrovirol,1997;14:223-31
  • 6Gable CB,Tierce JC,Simison D,Ward D,Motte K.Costs of HIV+/AIDS at CD4+counts disease stages based on treatment protocols[J].J Acquir Immune Defic Syndr Hum Retrovirol,1996;12:413-20
  • 7Chaisson RE,Moore RD,Richman DD,Keruly J,Creagh T.Zidovudine Epidemiology Study Group Incidence and natural history of Mycobacterium avium complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine[J].Am Rev Respir Dis,1992;146:283-89
  • 8Moore RD,Chaisson RE.Natural history of opportunistic diease in an HIV infected urban clinical cohort[J].Ann Intern Med,1996;124:633-42
  • 9Horsburgh CR Jr.Mycobacterium avium complex infection in the acquired immunodeficiency syndrome[J].N Engl J Med,1991;324:1332-8
  • 10Bacellar H,Munoz A,Hoover DR.Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cells counts 《100 cells·mm3:Multicenter AIDS cohort study[J].J Infect Dis,1994;170:1284-7

共引文献3

同被引文献48

  • 1吴小红.78种生药提取物对人肝脏微粒体CYP3A4和CYP2D6的抑制作用[J].国外医学(中医中药分册),2005,27(6):351-352. 被引量:7
  • 2朱莉贞,傅瑜,初乃惠,叶志忠,肖和平,王巍,苑松林,张侠,罗永艾,马丽萍.利福类联合多种药物长疗程方案治疗耐多药肺结核[J].中华结核和呼吸杂志,2006,29(8):520-523. 被引量:55
  • 3郑姣,周宏灏.黄酮类化合物对细胞色素P450 CYP1,2E1,3A4和19的影响[J].药学学报,2007,42(1):8-12. 被引量:27
  • 4MALFERTHEINER P, MEGRAUD F, O'MORAIN C, et 01. Current concepts in the management of Helicobacter pylori infection: the Maastricbt Ill Consensus Report[J]. Gut, 2007, 56(6) : 772-781.
  • 5BIERNAT MM, PONIEWIERKA E, BLASZCZUK J, et 01. Antimicrobial susceptibility of Helicobacter pylori isolates from Lower Silesia, Poland[J]. Arch Med Sci 2014, 10(3): 505-509.
  • 6FOCK KM, KATELARIS P, SUGANO K, et 01. Second Asia- Pacific consensus guidelines for Helicobacter pylori infection[J]. J Gastroenterology Hepatol, 2009, 24(10): 1587-1600.
  • 7PERRI F, FESTA V, CLIMENTE R, et ol. Rifabutin- based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens[J] Aliment Pharmacol Ther, 2000, 14: 311-316.
  • 8PERRI F, FESTA V, CLEMENTE R, et al. Randomized study of two"rescue"therapies for Helieobaeler pylori--infected patients after failure of standard triple therapies[J]. Am J Gastmentrol, 2001, 96(1): 58-62.
  • 9FINORINI G, VAKIL N, ZULLO A, et ol. Culture- based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection[J]. Clin Gastroenterol Hepatol, 2013, 11(5): 507-510.
  • 10MIEHLKE S, HANSKY K, SCHNEIDER-BRACHERT W, et a/. Randomized trial of rifabutin-based triple therapy and high- dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin[J]. Aliment Pharmacol Ther, 2006, 24(2): 395-403.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部